European Journal of Pediatrics 2015-04-01

Population pharmacokinetics of doxapram in low-birth-weight Japanese infants with apnea.

Yuki Ogawa, Mitsuru Irikura, Yuka Kobaru, Mayu Tomiyasu, Yoshie Kochiyama, Mamiko Uriu, Yoichi Ishitsuka, Yuki Kondo, Eiji Yukawa, Noboru Kamada, Hitoshi Ohno, Toshio Yamazaki, Tetsumi Irie

文献索引：Eur. J. Pediatr. 174(4) , 509-18, (2015)

全文：HTML全文

摘要

This study aimed to determine the population pharmacokinetics of doxapram in low-birth-weight (LBW) infants. A total of 92 serum concentration measurements that were obtained from 34 Japanese neonates were analyzed using nonlinear mixed-effect modeling (NONMEM). Estimates generated by NONMEM indicated that clearance of doxapram (CL; L/kg/h) was affected by postmenstrual age (PMA; weeks), body weight (BW; g), and aspartate aminotransferase (AST; IU/L). In addition, the volume of distribution (Vd; L/kg) was affected by gestational age (GA; weeks). The final pharmacokinetic model was as follows: CL = BW / PMA × 0.0453 × serum AST(-0.373); Vd = 2.54 (if GA >28 weeks) and Vd = 2.54 × 2.11 (if GA ≤28 weeks). The interindividual variabilities in CL and Vd were 39.9 and 83.0 %, respectively, and the residual variability was 20.9 %. To clarify the reasons for large interindividual variations, the enzymes involved in the metabolic pathway of doxapram were also determined. We found that doxapram was metabolized by CYP3A4/5.We report the population pharmacokinetics of doxapram in neonates and the involvement of CYP3A4/5 in its metabolism. The final model of population pharmacokinetics may be useful for formulating a safe and effective dosage regimen and for predicting serum doxapram concentrations in neonates.